Synopsis:
Recent reports have suggested that target-based approaches are useful but not informative enough and limit understanding the full pharmacology of drug actions. Some have suggested that phenotypic screening is a more successful approach to discovering novel drugs. Therefore, it is no surprise that phenotypic screening is making a comeback in drug discovery. This meeting will introduce the uses of phenotypic screening and systems pharmacology and will provide practical insights into some of the recent changes in its use and cover the benefits and issues in this area from a range of talks including case studies.
Attendees:
This meeting is targeted at all those who are involved in target selection and hit identification in drug discovery and those interested in furthering their knowledge of current and emerging approaches to these areas.
Programme:
09.30 Registration and refreshments
09.55 Welcome and introduction
10.00 The cellular uptake of pharmaceutical drugs is carrier-mediated and thus a problem not of biophysics but of systems biology, Professor Douglas Kell, University of Manchester
10.45 Novel macrolide inspired macrocycles, the rule breakers for 鈥淗ard Targets鈥�, identified by phenotypic screening, Dr Gordon Saxty, Fidelta
11.20 Phenotypic screening using human primary cell based assays, Dr Jeroen DeGroot, BioFocus
12.00 Lunch and exhibition
13.15 Hit to lead optimisation of novel antimalarial chemotypes derived from selected HTS campaigns, Dr Paul O鈥橬eil, Liverpool University
13.50 Speaker to be advised
14.30 A chemogenomic approach to elucidating a mechanism for directing stem cell differentiation, Dr Robert Owen, Pfizer
15.00 Refreshment break
15.20 In silico approaches to support mode-of-action analysis using chemical and biological data, Dr Andreas Bender, University of Cambridge
15.50 Zebrafish phenotypic screens for anti-inflammatory (or pro-resolution) drug discovery, Professor Steve Renshaw, University of Sheffield
16.20 Integrating phenotypic screens with in vivo imaging and reverse phase protein array technologies to advance translation, Dr Neil Carragher, Edinburgh Cancer Research Centre
17.10 Closing remarks
Organising Committee:
Dr Adrian Longstaff, Syngenta
Dr Nat Monck, Evotec
Dr Joanne Pinder, Vertex
Exhibition:
An exhibition will take place alongside the conference during refreshment breaks for companies and related organisations who may wish to exhibit. For further information and prices, please email conferences@soci.org. Spaces are limited and will be allocated on a first come, first served basis.
Delegate Fees:
Early Bird Fees - before 6 February 2015
SCI Member GB拢100
SCI Student Member GB拢35
SCI Subsidised Member GB拢65
Non-Member GB拢135
Standard Fees - after 6 February 2015
SCI Member GB拢120
SCI Student Member GB拢45
SCI Subsidised Member GB拢80
Non-Member GB拢165
Recent reports have suggested that target-based approaches are useful but not informative enough and limit understanding the full pharmacology of drug actions. Some have suggested that phenotypic screening is a more successful approach to discovering novel drugs. Therefore, it is no surprise that phenotypic screening is making a comeback in drug discovery. This meeting will introduce the uses of phenotypic screening and systems pharmacology and will provide practical insights into some of the recent changes in its use and cover the benefits and issues in this area from a range of talks including case studies.
Attendees:
This meeting is targeted at all those who are involved in target selection and hit identification in drug discovery and those interested in furthering their knowledge of current and emerging approaches to these areas.
Programme:
09.30 Registration and refreshments
09.55 Welcome and introduction
10.00 The cellular uptake of pharmaceutical drugs is carrier-mediated and thus a problem not of biophysics but of systems biology, Professor Douglas Kell, University of Manchester
10.45 Novel macrolide inspired macrocycles, the rule breakers for 鈥淗ard Targets鈥�, identified by phenotypic screening, Dr Gordon Saxty, Fidelta
11.20 Phenotypic screening using human primary cell based assays, Dr Jeroen DeGroot, BioFocus
12.00 Lunch and exhibition
13.15 Hit to lead optimisation of novel antimalarial chemotypes derived from selected HTS campaigns, Dr Paul O鈥橬eil, Liverpool University
13.50 Speaker to be advised
14.30 A chemogenomic approach to elucidating a mechanism for directing stem cell differentiation, Dr Robert Owen, Pfizer
15.00 Refreshment break
15.20 In silico approaches to support mode-of-action analysis using chemical and biological data, Dr Andreas Bender, University of Cambridge
15.50 Zebrafish phenotypic screens for anti-inflammatory (or pro-resolution) drug discovery, Professor Steve Renshaw, University of Sheffield
16.20 Integrating phenotypic screens with in vivo imaging and reverse phase protein array technologies to advance translation, Dr Neil Carragher, Edinburgh Cancer Research Centre
17.10 Closing remarks
Organising Committee:
Dr Adrian Longstaff, Syngenta
Dr Nat Monck, Evotec
Dr Joanne Pinder, Vertex
Exhibition:
An exhibition will take place alongside the conference during refreshment breaks for companies and related organisations who may wish to exhibit. For further information and prices, please email conferences@soci.org. Spaces are limited and will be allocated on a first come, first served basis.
Delegate Fees:
Early Bird Fees - before 6 February 2015
SCI Member GB拢100
SCI Student Member GB拢35
SCI Subsidised Member GB拢65
Non-Member GB拢135
Standard Fees - after 6 February 2015
SCI Member GB拢120
SCI Student Member GB拢45
SCI Subsidised Member GB拢80
Non-Member GB拢165
